Wire · opportunities
Lilly's Mounjaro Now Approved to Reduce Cardiovascular Risk in T2D
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
Eli Lilly's Mounjaro (tirzepatide) has received FDA approval to reduce cardiovascular risk in adults with type 2 diabetes based on the SURPASS-CVOT trial showing noninferiority to dulaglutide in reducing major adverse cardiovascular events.
This Wire brief sits within Fusion42's coverage of Health: Biotech, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
Your type 2 diabetes product now competes with Mounjaro's expanded label for cardiovascular risk, pressing urgency on differentiating beyond glycemic control. Cardiometabolic-focused Biotech founders must note this FDA nod opens new market demands for comprehensive risk reduction.
◆ Coverage
20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026
◆ Topics